Skip to main
NAMS
NAMS logo

NAMS Earnings Dates & Reports

NAMS Most Recent Earnings

Report DateMay 8, 2025
Period EndingQ1 2025
Est. EPS-$0.44
Actual EPS-$0.34
EarningsBeat

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

NAMS Earnings per Share (EPS) History

Signup for full access
Browse free

NAMS Latest Earnings

The value each NAMS share was expected to gain vs. the value each share gained.

NAMS reported its most recent earnings on May 8, 2025 for Q1 2025, posting earnings per share (EPS) of -$0.34. This exceeded analysts' expectations of -$0.44 by 22.73%, marking a Beat.

For comparison, Newamsterdam Pharma Co NV reported EPS of $0 in the same quarter last year.

The company is expected to announce its next earnings report on 08/06/2025, with analysts projecting an EPS of $0.

NAMS Earnings History

Earnings
Est. EPSActual EPSSurprise
Q2 2025Aug 6, 2025
Next earnings call Aug. 6, 2025
Q1 2025May 8, 2025
-$0.44-$0.34-22.73%
DeckReportListen
Q4 2024Feb 26, 2025
-$0.51
Q3 2024Nov 6, 2024
-$0.18

NAMS Earnings Related Price Changes

Earnings announcements may impact a stock’s price. This table highlights the Newamsterdam Pharma Co NV’s price movement by comparing the day-before and day-after prices of recent earnings reports, along with the percentage change.

Report datePrice 1D beforePrice 1D afterChange
May 8, 2025
Feb 26, 2025
Nov 6, 2024

NAMS Earnings FAQs

NAMS last reported earnings on May 8, 2025 for Q1 2025, posting an EPS of -$0.34, which Beat the estimate of -$0.44 by 22.73%.

For Q1 2025, NAMS reported an EPS of -$0.34, exceeding analysts' estimate of -$0.44 by 22.73%.

For Q1 2025, NAMS Beat expectations with an actual EPS of -$0.34 vs. an estimated EPS of -$0.44.

Following the last earnings report on May 8, 2025, NAMS's stock price moved — from — to —.

The next NAMS earnings call is scheduled for Aug. 6, 2025, where executives will discuss financial results and outlook.

Newamsterdam Pharma Co NV (NAMS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.